ALSO NOTED: Bentley spins off drug delivery biz; Immunosyn names new CEO; and much more...

> Bentley Pharmaceuticals plans to spin off its drug delivery business into a separate company while it explores its options on its generics business. Report

> Schering-Plough posted strong profits and double-digit sales growth yesterday--but its stock plunged. Report

> Chutes & Ladders: La Jolla, CA-based Immunosyn has signed up Stephen D. Ferrone as its new CEO. Release

> PURE Bioscience has garnered new funds from the sale of securities. Release

> The tug-of-war over anemia drugs rages on. Now, cancer specialists say there's no clinical data to support Medicare's restrictions on the drugs, made by Amgen and Johnson & Johnson. Report

> Glaxo has given Mylan the patent licenses that allow it to sell Paxil ER beginning in October 2008. Report

> Scientists at Manchester University have grown new peripheral nerves by using stem cells extracted from fat, and they are suggesting that the new therapy may be available to patients in as little as four years. Report

> A group of researchers at Brigham and Women's Hospital in Boston are focused on developing a new, nonhormonal contraceptive that uses RNAi technology to silence the ZP3 gene, which is required to fertilize an egg during ovulation. Report

And Finally... Genetic variations may be used to predict the progression of HIV infection to AIDS. Report

Suggested Articles

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.